Specialty pharmaceutical and consumer healthcare company Norgine announced on Friday the validation of X4 Pharmaceuticals' Marketing Authorization Application for mavorixafor by the European Medicines Agency's Committee for Medicinal Products for Human Use.
Mavorixafor, an oral, once-daily treatment for WHIM syndrome, was approved by the US Food and Drug Administration in April 2024 under the name XOLREMDI for patients aged 12 and older.
This regulatory progress follows a licensing agreement between Norgine and X4 Pharmaceuticals. Efforts are underway to facilitate access to mavorixafor in Europe, Australia and New Zealand. Achieving this milestone represents a significant step toward addressing the needs of patients with this rare primary immunodeficiency.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval